Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study

Limited data are available about mitotane-nduced hyperlipidemia. We retrospectively analyzed lipid data in 38 patients with adrenocortical carcinoma (ACC) who received mitotane therapy with emphasis on HDL cholesterol (HDL-c) and clinical predictors of lipid changes. At baseline, the mean levels of...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Endocrinology Vol. 2013; no. 2013; pp. 225 - 231-128
Main Authors Shawa, Hassan, Deniz, Ferhat, Bazerbashi, Hadil, Hernandez, Mike, Vassilopoulou-Sellin, Rena, Jiménez, Camilo, Habra, Mouhammed Amir
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Limiteds 01.01.2013
Hindawi Puplishing Corporation
Hindawi Publishing Corporation
John Wiley & Sons, Inc
Hindawi Limited
Subjects
Body mass index
Cholesterol
Cohort analysis
Dosage and administration
Endocrinology
Fatty acids
Health aspects
Hyperlipidemia
Lipids
Mitotane
Neuroendocrine tumors
Patients
Standard deviation
Statins
Triglycerides
Texas
Online AccessGet full text

Cover

More Information
Summary:Limited data are available about mitotane-nduced hyperlipidemia. We retrospectively analyzed lipid data in 38 patients with adrenocortical carcinoma (ACC) who received mitotane therapy with emphasis on HDL cholesterol (HDL-c) and clinical predictors of lipid changes. At baseline, the mean levels of HDL-c, LDL-c, and triglycerides were 53.3 mg/dL, 114.4 mg/dL, and 149 mg/dL, respectively. HDL-c, LDL-c, and triglyceride concentrations significantly increased with mitotane therapy to a mean HDL peak (HDL-P) of 86.3 mg/dL (P<0.001), a mean LDL peak of 160.1 mg/dL (P<0.001), and a mean triglyceride peak (Tg-P) of 216.7 mg/dL (P=0.042). HDL-P positively correlated with mitotane concentration (r=0.52,P<0.001), while LDL-P levels and Tg-P did not. Gender, body mass index, cortisol overproduction, baseline levels of HDL-c, and triglyceride did not predict change in HDL-c. Similar changes were noticed in subgroup analysis after excluding patients who were using lipid-lowering agents. In conclusion, in ACC patients, mitotane caused significant increases in HDL-c that may counteract the deleterious atherosclerotic effects of LDL-c and Tg rise. Understanding the mechanism of HDL change may lead to the discovery of novel HDL-c-elevating drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Academic Editor: Stephen L. Atkin
ISSN:1687-8337
1687-8345
DOI:10.1155/2013/624962